Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Fos-related antigen 1 (FRA1) is overexpressed in aggressive murine breast carcinoma.
• Developing effective breast cancer therapies remains a critical challenge.

Purpose of the Study:

• To evaluate the efficacy of an oral DNA vaccine against FRA1 for breast cancer treatment.
• To investigate the immunological mechanisms and anti-angiogenic effects of the vaccine.

Main Methods:

• An oral DNA vaccine was constructed using attenuated Salmonella typhimurium, encoding FRA1 fused with mutant polyubiquitin and co-expressing IL-18.
• The vaccine's impact on primary tumor growth, pulmonary metastasis, and survival was assessed in a murine breast cancer model.
• Immunological responses, including immune cell activation, cytokine release, and angiogenesis suppression, were analyzed.

Main Results:

• The DNA vaccine markedly suppressed primary tumor growth and pulmonary metastasis.
• Vaccinated mice exhibited tripled lifespan with no detectable tumor growth after lethal challenge.
• The vaccine activated T cells, NK cells, and dendritic cells, enhancing target cell lysis and proinflammatory cytokine release (IFN-gamma, IL-2).
• Significant suppression of tumor angiogenesis was observed in vaccinated animals.

Conclusions:

• This multifunctional oral DNA vaccine is effective against breast cancer growth and metastasis.
• The vaccine combines immune cell activation with anti-angiogenic properties for comprehensive anti-tumor activity.
• Further research into this novel DNA vaccine strategy holds promise for breast cancer treatment.